815 related articles for article (PubMed ID: 29102254)
1. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
[TBL] [Abstract][Full Text] [Related]
2. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
3. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
4. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
5. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
[TBL] [Abstract][Full Text] [Related]
6. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
7. Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.
Reignier PL; Gauthier H; Hennequin C; Aussedat Q; Xylinas E; Desgrandchamps F; Culine S; Masson-Lecomte A; Dumont C
World J Urol; 2023 Nov; 41(11):3249-3255. PubMed ID: 37410102
[TBL] [Abstract][Full Text] [Related]
8. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
Arcangeli G; Strigari L; Arcangeli S
Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
[TBL] [Abstract][Full Text] [Related]
9. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
12. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
Hautmann RE; de Petriconi RC; Pfeiffer C; Volkmer BG
Eur Urol; 2012 May; 61(5):1039-47. PubMed ID: 22381169
[TBL] [Abstract][Full Text] [Related]
13. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
Mak KS; Smith AB; Eidelman A; Clayman R; Niemierko A; Cheng JS; Matthews J; Drumm MR; Nielsen ME; Feldman AS; Lee RJ; Zietman AL; Chen RC; Shipley WU; Milowsky MI; Efstathiou JA
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1028-1036. PubMed ID: 27727064
[TBL] [Abstract][Full Text] [Related]
14. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
15. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F
Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232
[TBL] [Abstract][Full Text] [Related]
17. Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
Su X; Dong C; Liao W; Liu W
World J Surg Oncol; 2023 Aug; 21(1):271. PubMed ID: 37641150
[TBL] [Abstract][Full Text] [Related]
18. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
19. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
Softness K; Kaul S; Fleishman A; Efstathiou J; Bellmunt J; Kim SP; Korets R; Chang P; Wagner A; Olumi AF; Gershman B
Urol Oncol; 2022 Jun; 40(6):272.e1-272.e9. PubMed ID: 35058142
[TBL] [Abstract][Full Text] [Related]
20. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]